Methodological Note – 2021
Accompanying document for the public Disclosure concerning transfers of value to Patient Organizations

Takeda Pharma AB
Date written: 2022-06-01
Notes on the PO Methodology 2021

1. General introduction 3

2. Scope of Disclosure 3

2.1. Interaction with Patient Organizations (POs) 3

   2.1.1. Patient Organization (PO): definition and specific requirements

     *Bookmark not defined.*

   2.1.2. Time of Disclosure 3

2.2. How transfer of value (TOVs) is provided 3

2.3. Activities within the scope of Disclosure 4

   2.3.1. Donations and grants 4

   2.3.2. Contribution to events costs and Sponsorship 4

   2.3.3. Service and consultancy fees 4

2.4. Cross-border value transfer 5

3. Assumptions 5

3.1. Date of transfer of value 5

3.2. Currency 5

3.3. Taxes 5

4. Conflict management 5
1. General introduction
Collaboration between the industry and patient organizations is beneficial to patients. This relationship has delivered numerous innovative medicines and changed the way many diseases affect our lives. Greater transparency in this important, already well-regulated relationship, should help to create a stable foundation for future collaboration. Society has ever-increasing expectations regarding transparency, especially in healthcare sector. As a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), we aim to ensure that we meet these expectations in the future.

This methodological note is intended for all those who wish to better understand the assumptions behind the creation of the patient organization disclosure report and how the disclosed activities are defined.

2. Scope of Disclosure
We have summarized below our interpretation and working assumptions along with a definition of recipients and expenses that are in scope.

2.1. Interaction with Patient Organizations (POs)

2.1.1. Patient Organization (POs): definition and specific requirements

Patient Organization (PO) is a non-for-profit legal person/entity (including the umbrella organization to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and which business address, place of incorporation or primary place of operation is in an EFPIA member country.

Patient organization representative is a person who is mandated to represent and express the collective views of a PO on a specific issue or disease area.

2.1.2. Time of disclosure
The reporting period refers to the annual disclosure cycle and covers a full prior calendar year. The common reporting period for publication of the transfer of values to the patient organization is set during the time interval from 30th June each following year at the latest. Where a national code provides a different time interval for its country, this must consistently apply to all disclosure obligations to recipients.

2.2. How the Transfer of Value (ToVs) is provided
Direct: payments made directly to the patient organization

Indirect: payments made through an intermediary (third party) on behalf of Takeda.

In-Kind: is a non-monetary support provided to benefitting patient organization.

Payment to individual patients who do not represent or are not hired through a patient organization are not subject to disclosure
For example:
2.3. Activities within the scope of disclosure

The definitions of activities can differ from one company to the next. At Takeda, all our interactions with patient organizations are governed by internal policies and standard operating procedures which have been created in accordance with the industry codes and guidelines, local country-specific laws and principles, and local industry requirements. Below you will find the EFPIA definitions.

Types of the support or services provided:

I. Financial support

II. Significant indirect support: It is a support provided by a member company to a patient organization through a third party

III. Non-financial support: It is when a member company provides a service to a patient organization without paying the PO. For example, when a member company lends a meeting room in its office to a patient organization. In that case, this service does not cost anything to the member company but there is a monetary value for this service that must be disclose i.e. the cost of renting a similar meeting room in a hotel

IV. Contracted services

2.3.1. Donations and grants to POs

All transfers of value related to donations or grants to a PO are included within the scope of the Disclosure. Such transfers of value include:

i. Donations – financial support

ii. Benefits in kind – non-financial support

iii. Charitable donations (if the organization is classified in the country as a patient organization) financial and/or non-financial support

They do not constitute an inducement to recommend and/or prescribe, purchase, supply, sell or administer specific medical products.

Donations and grants to individuals are not permitted

As per local code Sweden may only provide Grants/Donation for research purpose.

2.3.2. Contribution to events costs - Sponsorship

Any transfer of value in terms of contributions towards events costs directly or indirectly through a third party are covered by the scope of the disclosure and published as significant indirect support. Such transfers of value include, for example:

i. A sponsorship agreement with patient organisation or a nominated third party for managing an event, such as scientific conferences, congresses, or exhibitions by third parties.

2.3.3. Service and consultancy fees

Any transfer of value related to service and consultancy fees are included within the scope of the Disclosure and published as contracted services. Such transfers of value include, for example, a meeting or event where some PO representative appears as a speaker, trainer, or consultant. These include, among others:
ii. Fees (fees for services such as preparation time, rehearsal time, travel time, and time expended on the activity)

iii. Related costs (e.g., travel expenses, accommodation)

The arrangements that cover consultancy or other services have a written contract, the service is agreed in advance of the commencement of the services which specifies the nature of the services to be provided and the basis for payment of those services and will be disclosed in the name of the patient organization.

2.4. Cross-border transfer of value
Cross-border activities are considered when a PO is engaged or sponsored by any part of the company other than the country of the patient organization. We associate the transfer of value to the country where the principal address of the patient organization is located. Cross-border value transfers are included in our disclosure report.

3. Assumptions

3.1. Date of transfer of value

The transfers of value will be disclosure in this report based on the payment dates.

If the payment date was between 1st January and 31st of December the same year, the payment will be included in our next disclosure report published in June.

Example: If an activity happens at the end of 2020 but the payment does not happen in 2020 but was made at the beginning of 2021, we will disclosure this payment in our report 2022.

Payments made at the end of 2021 for an activity completed in early 2022 will be regarded as value transfers in 2021 for disclosure in June 2022.

3.2. Currency
The currency is clearly posted in our report.

If value is transferred in a currency other than the official local currency, the amount will be converted using the monthly updated exchange rates of the Takeda Company Treasury.

3.3. Taxes
The sums stated in our Report are gross amounts. Expenses such as for travel and accommodation are subject to sales tax. The documented and disclosed figures exclude sales tax.

4. Conflict management
Takeda has introduced an internal conflict management process with which to handle, for example, any general questions and inconsistencies relating to the published data and/or requests for addition or removal of the information.

If you have any comments or questions concerning the processing of your data by Takeda, this methodological note, the content of the Disclosure, or the privacy policy please send us a short note transparency@takeda.com or use the contact named on the Takeda local website.